Gabbai to lead investment firm

Eyal Gabbai, former director-general of the Government Companies Authority, was named head of a new Israel office of the international investment and advisory firm Babcock & Brown, said the company on Tuesday.

By YONI TEITZ
June 20, 2007 07:57

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For a symbolic $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Don't show it again

Eyal Gabbai, former director-general of the Government Companies Authority, was named head of a new Israel office of the international investment and advisory firm Babcock & Brown, said the company on Tuesday. In his previous position as director-general of the GCA, Gabbai led the privatization of El Al, Bezeq and the Israel Oil Refineries, and was involved in developing and restructuring Israeli ports, Railway Authority, postal services and electricity markets. Babcock & Brown, based in Australia, has expertise in the areas of real estate, infrastructure and project finance, operating leasing, and structured and corporate finance.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS